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Introduction {#sec1}
============

Population expansion, cultural changes, and migration during the last 100,000 years exposed humans to pathogens against which they had not evolved effective resistance. Host genetics strongly influence susceptibility to infectious disease, with pathogens that affect reproductive fitness imposing selection on genes that impact disease outcomes ([@bib40]). Nowhere in the human genome are these effects more evident than in the *HLA* region ([@bib55]). Because of their vital role in providing immunity against diverse and rapidly evolving pathogens, the *HLA*-*A*, -*B*, and -*C* genes have been subject to strong balancing selection, making them the most diverse of human genes ([@bib6], [@bib70]). *HLA-A*, *-B*, and -*C* arose by a series of gene duplications from a common ancestral *MHC class I* gene ([@bib56]). These genes also serve as a reservoir of polymorphic sequences that can be recombined to create new *HLA* alleles that can provide protection against emerging pathogens. Although such new variants are thought to arise in human populations during episodes of Darwinian selection, there is little direct evidence for the nature of the process. *HLA-B^∗^46:01* provides a compelling example of such an episode.

*HLA-B^∗^46:01* has restricted distribution in Southeast Asia where it likely originated around the time of the arrival of modern humans ∼50,000 years ago ([@bib1], [@bib28]). It most likely rose in frequency following a selective sweep of the type more often seen in small, isolated populations ([@bib1]), and it is now carried by ∼110 million individuals of Southeast Asian descent ([@bib28]). Despite its high frequency, *HLA-B^∗^46:01* is an unusual allele, formed by the recombination between *HLA-B^∗^15:01* and *HLA-C^∗^01:02*. Similar intergenic recombinants have been identified ([@bib33], [@bib66]), but none is found at comparable frequency, suggesting that *HLA-B^∗^46:01* fills an immunological niche not afforded by either parent or any other *HLA class I* variant found in the region. Supporting this notion, epidemiologic studies suggest that *HLA-B^∗^46:01* may confer protection against *Mycobacterium leprae*, the causative agent of leprosy, which is endemic to Southeast Asia ([@bib74]).

HLA class I glycoproteins are found on virtually all human cells, where they act as ligands for the killer-cell immunoglobulin-like receptors (KIRs) of natural killer (NK) cells and the T cell receptors (TCRs) of cytotoxic CD8 T cells ([@bib18], [@bib80]). A key feature of HLA class I is a short peptide, produced by intracellular protein degradation, that is bound during assembly of the HLA in the endoplasmic reticulum. KIRs and TCRs recognize the upper face of HLA and its bound peptide ([@bib10], [@bib23], [@bib27]). TCR recognition is exquisitely sensitive to the sequence of the bound peptide. KIR binding appears less so, though the rules that govern the peptide specificity of KIR have yet to be fully defined.

Structural, functional, and genetic studies of *HLA class I* and its counterparts in non-human primates support a model in which *HLA-A* and *-B* evolved to become the major TCR ligands, whereas *HLA-C* evolved the C1 and C2 epitopes to become the principal KIR ligands ([@bib29]). In this context, HLA-B^∗^46:01 is an exceptional allotype that carries the C1 epitope and functions as a KIR ligand ([@bib5], [@bib78]). As part of their functional specialization, HLA-A, -B, and -C bind distinctive sets of peptides and are distinguished by locus-specific polymorphisms and differences in cell-surface expression ([@bib47], [@bib64], [@bib71], [@bib77]).

HLA-B^∗^46:01 differs from HLA-B^∗^15:01 at residues 66--76 of the α~1~ helix that derive from HLA-C^∗^01:02 ([@bib78]). Within this 11-residue segment, HLA-B^∗^46:01 differs from HLA-B^∗^15:01 at seven positions (K66I, Y67S, R69T, Q70N, A71T, D74Y, and V76E). Val76 is essential for the C1 epitope ([@bib5], [@bib7]), and the KYRV motif at positions 66, 67, 69, and 76 reduces cell-surface expression of HLA-B^∗^46:01 ([@bib64]). Contributing to the TCR- and KIR-binding sites are residues 66, 69, 70, 71, 74, and 76 ([@bib10], [@bib23], [@bib27]). Because residues 66--76 comprise half of the polymorphic positions in the binding groove, they are predicted to influence the peptide-binding specificity of HLA-B^∗^46:01.

Prior to this study, knowledge of the HLA-B^∗^46:01 peptidome was limited to six peptides ([@bib5]). Here we define at high resolution the peptidomes of HLA-B^∗^46:01 and its parents. We then identify those peptides that provide ligands for the C1-specific NK cell receptor, KIR2DL3. Comparison of \>6,000 HLA-B^∗^15:01-binding peptides, \>2,000 HLA-B^∗^46:01-binding peptides, and \>750 HLA-C^∗^01:02-binding peptides shows how the recombination that created HLA-B^∗^46:01 gave it a peptidome that is completely different from that of its parents. Its distinctive peptide-binding site appears well suited to bind antigenic peptides derived from *M. leprae.*

Results {#sec2}
=======

HLA-B^∗^46:01, HLA-B^∗^15:01, and HLA-C^∗^01:02 Have Distinctive Peptidomes {#sec2.1}
---------------------------------------------------------------------------

To compare the peptides bound by HLA-B^∗^46:01 and its parental allotypes, we isolated these HLA molecules, eluted the bound peptides, and determined their sequences by mass spectrometry. We identified 6,387 peptides for HLA-B^∗^15:01, 788 for HLA-C^∗^01:02, and 2,115 for HLA-B^∗^46:01 ([Figure 1](#fig1){ref-type="fig"} A). This is consistent with previous reports showing that HLA-C peptide repertoires are generally smaller and less diverse than those of HLA-A and -B ([@bib52], [@bib57]). The intermediate size of the HLA-B^∗^46:01 peptidome is consistent with its binding site being a hybrid of the parental allotypes.Figure 1HLA-B^∗^46:01, HLA-B^∗^15:01, and HLA-C^∗^01:02 Have Distinctive Peptidomes(A) Venn diagram showing each peptidome represented by a color-shaded circle: HLA-B^∗^15:01 (red), HLA-C^∗^01:02 (blue), and HLA-B^∗^46:01 (orange). The area of the circle is proportional to the number of distinct peptides (number shown in center of circle). The area of each circle overlap is proportional to the number of shared peptides (number shown within or beside each overlap) that bind to the two allotypes.(B) Listed are the total number of peptides bound by HLA-B^∗^15:01 (red), HLA-C^∗^01:02 (blue), or HLA-B^∗^46:01 (orange); the proportion bound by only that allotype (% distinct); as well as the proportion shared by pairs of allotypes (% shared with).(C) For each allotype the histogram divides the binding peptides according to length, given as the number of amino acid residues.(D) The proportion of peptides (%) that bind to one allotype (upper panel) or are shared by two allotypes (lower panel) plotted according to their length. The peptides shared by HLA-B^∗^15:01 and HLA-C^∗^01:02 are not plotted because they are too few.

A majority (84.2%) of the peptides characterized is specific for one of the three HLAs, while only 15.8% bind to two of the three HLA class I molecules, and only one peptide, TSSYKPIV, binds all three ([Figure 1](#fig1){ref-type="fig"}A; [Figure S1](#mmc1){ref-type="supplementary-material"}). Consistent with the similarity of their primary structures, the HLA-B^∗^15:01 and HLA-B^∗^46:01 peptidomes have the greatest overlap, with 333 shared peptides ([Figure 1](#fig1){ref-type="fig"}B). Although the sequences of the peptide-binding domains of HLA-B^∗^15:01 and HLA-B^∗^46:01 differ only by 3.8%, their peptidomes differ by \>84%.

Consistent with their gene-specific polymorphisms ([@bib71], [@bib77]), the peptide-binding domains of HLA-B^∗^15:01 and HLA-C^∗^01:02 differ by 14.4%, and these allotypes have only three peptides in common ([Figure 1](#fig1){ref-type="fig"}B). The peptide-binding domains of HLA-C^∗^01:02 and HLA-B^∗^46:01 differ by 10.6%, and these allotypes have 19 common peptides. Thus, the gene conversion that created HLA-B^∗^46:01 gave it a new and distinctive peptidome.

The HLA-B^∗^46:01 Peptidome Is Skewed toward Nonamer Peptides {#sec2.2}
-------------------------------------------------------------

We identified differences in the lengths of peptides bound by each allotype ([Figure 1](#fig1){ref-type="fig"}C). HLA-B^∗^15:01-binding peptides exhibit a wide range in length: a minority (44%) are nonamer peptides and ∼30% are longer than decamers ([Figure 1](#fig1){ref-type="fig"}D). With a majority (54%) of HLA-C^∗^01:02-binding peptides being nonamers, their range is narrower than those of HLA-B^∗^15:01 ([Figure 1](#fig1){ref-type="fig"}D, upper panel). HLA-B^∗^46:01-binding peptides have the narrowest range, with \>80% of them being nonamers or decamers ([Figure 1](#fig1){ref-type="fig"}D, upper panel). Among the 333 peptides shared by HLA-B^∗^15:01 and B^∗^46:01, ∼75% are nonamers ([Figure 1](#fig1){ref-type="fig"}D, lower panel; [Figure S1](#mmc1){ref-type="supplementary-material"}). Thus, the skewing of HLA-B^∗^46:01 peptides for nonamers is more pronounced in peptides also bound by HLA-B^∗^15:01. This contrasts with those shared with HLA-C^∗^01:02, of which only 37% are nonamers ([Figure 1](#fig1){ref-type="fig"}D, lower panel). Thus, HLA-B^∗^46:01 has a peptide-binding site with stronger selectivity for nonamer peptides than either parent.

HLA-B^∗^46:01 Incorporates Elements from Both Parents in Its Peptide-Binding Motif {#sec2.3}
----------------------------------------------------------------------------------

We next identified the amino acid preference of each peptidome. Peptides bound by HLA-B^∗^15:01 and HLA-B^∗^46:01 usually have Tyr, Phe, Leu, or Met at P9, and they share a similar, though less conserved, preference for Lys or Ile at P3. These properties are consistent with HLA-B^∗^15:01 and HLA-B^∗^46:01 having sequence identity in the F and D pockets that bind P9 and P3, respectively ([Figure S1](#mmc1){ref-type="supplementary-material"}E).

By contrast, at P2, HLA-B^∗^15:01 and HLA-B^∗^46:01 have divergent preferences. Although both bind peptides with Leu at P2, Gln is abundant in HLA-B^∗^15:01 peptides (26%) whereas Ala is most common in HLA-B^∗^46:01 peptides (28%) ([Figure 2](#fig2){ref-type="fig"} A). Like HLA-B^∗^46:01, HLA-C^∗^01:02 binds peptides with Ala and Leu at P2 (32% and 17%, respectively), as well as peptides with Ser at P2 (20%). Thus, all three allotypes commonly bind peptides with Leu at P2, the most common amino acid in peptides bound by HLA-B^∗^15:01, but not in those bound by HLA-B^∗^46:01 or HLA-C^∗^01:02 where Ala predominates. These results correlate with the sequences at positions 66--70 of the B pocket, which are identical in HLA-C^∗^01:02 and HLA-B^∗^46:01, but not in HLA-B^∗^15:01 ([Figure S1](#mmc1){ref-type="supplementary-material"}E). HLA-B^∗^46:01 and HLA-C^∗^01:02 share a common motif (Glu, Ala, or Ser) at position 8. This is an unexpected finding as the HLA backbone places limited constraint on P8 ([@bib10]). One possibility is that Val76, a residue shared by HLA-B^∗^46:01 and HLA-C^∗^01:02, mediates this effect. HLA-B^∗^46:01 also acquired new properties in peptide selection. This is most evident at P1 where Phe and Tyr are common, but not in either parent ([Figure 2](#fig2){ref-type="fig"}A). The HLA^∗^C^∗^01:02 motif is different from the four broad motifs described for HLA-C ([@bib57]), in having Pro at P3 and Leu at P9 in \>85% of its peptides.Figure 2HLA-B^∗^46:01 Binds a Subset of Peptides with a Distinctive Amino Acid Motif and Biochemical Properties(A) Kullback-Leibler sequence logos showing amino acid preferences for nonamer peptides bound by HLA-B^∗^15:01 (left), HLA-B^∗^46:01 (center), and HLA-C^∗^01:02 (right). Each logo consists of stacks of amino acid symbols, one stack for each position in the sequence. The total height of the column of amino acids represents the level of conservation at that position, and the residue height denotes its relative frequency. The colors of each amino acid correspond to their biochemical characteristics: acidic (red), basic (blue), hydrophobic (black), and polar (green). Sequence logos were generated using WebLogo ([@bib19]).(B) Covariation matrices for nonamer peptides bound by each allotype. The color of each square represents the conservation at or covariation between the listed residues on a heatmap scale, with blue indicating weak covariation and red indicating strong covariation.(C) PCA density plots show the distribution of nonamer peptides bound by HLA-B^∗^15:01 (left, red), HLA-B^∗^46:01 (center, orange), and HLA-C^∗^01:02 (right, blue). For comparison, in each plot the distribution of nonamer peptides from the other allotypes is shown in gray. The percentage of the variation in the dataset shown by the first (PC1) and second (PC2) principal components is listed to the left.

Subsets of HLA-B^∗^46:01-Binding Peptides Resemble HLA-B^∗^15:01- or HLA-C^∗^01:02-Binding Peptides {#sec2.4}
---------------------------------------------------------------------------------------------------

A covariation matrix was used to identify conserved pairs of amino acids in nonamer peptides bound by each allotype ([Figure 2](#fig2){ref-type="fig"}B). In the peptides bound by HLA-B^∗^15:01 and HLA-B^∗^46:01, pairs of residues at P2 and P9 are conserved. The most common motif observed in HLA-B^∗^15:01 (∼35%) and HLA-B^∗^46:01 (∼30%) peptides combines Leu at P2 with Tyr at P9. Both allotypes have a second, less common motif: Gln at P2 with Leu at P9 in HLA-B^∗^15:01 and Ala at P2 with Leu at P9 in HLA-B^∗^46:01 ([Figure S2](#mmc1){ref-type="supplementary-material"}). For HLA-C^∗^01:02 peptides, pairs of residues at P2 and P3 and at P3 and P9 are conserved. These peptides combine Ala at P2 with Pro at P3 and Pro at P3 with Leu at P9 ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Reflecting its hybrid structure, HLA-B^∗^46:01- and HLA-B^∗^15:01-binding peptides share the Leu2/Tyr9 9 pair of residues, whereas the HLA-B^∗^46:01- and HLA-C^∗^01:02-binding peptides share the Ala2/Leu9 pair of residues. Covariation between pairs of amino acid residues in peptides bound by MHC has been previously observed ([@bib8]), with structural analyses indicating it occurs due to alterations in the register of the peptide backbone, causing compensatory changes along the peptide-MHC interface ([@bib16], [@bib26], [@bib41]).

Extending this analysis, we relaxed the requirement for conserved pairs of identical amino acids, and we compared the biochemical properties of each peptidome by principal-component analysis (PCA) ([Figure 2](#fig2){ref-type="fig"}C). The HLA-B^∗^15:01 peptidome forms a single dominant cluster, contrasting with a small tight cluster formed by that of HLA-C^∗^01:02. There is little spatial overlap between these peptidomes, indicating that they contain biochemically distinct peptides. The HLA-B^∗^46:01 peptidome is more diffuse, resembling a fusion of the two parents. The larger cluster overlaps with that of HLA-B^∗^15:01, the smaller one with HLA-C^∗^01:02. These results are consistent with the covariation analysis ([Figure 2](#fig2){ref-type="fig"}B; [Figure S2](#mmc1){ref-type="supplementary-material"}), and they show that HLA-B^∗^46:01 presents two subsets of peptides that are biochemically similar, but not identical, to those of its parents.

A Minority of HLA-B^∗^46:01 and HLA-C^∗^01:02 Peptides Are Strong KIR2DL3 Ligands {#sec2.5}
---------------------------------------------------------------------------------

HLA-B^∗^46:01 and HLA-C^∗^01:02, but not HLA-B^∗^15:01, carry the C1 epitope and are recognized by KIR2DL3 ([@bib50]). To determine if KIR2DL3 displays a preference for specific peptide combinations, we incubated KIR2DL3-coated beads with sHLA, isolated the bound peptides, and determined their sequences by mass spectrometry. We call these peptides KIR permissive, as they enable the HLA molecule to be recognized by KIR2DL3.

No KIR-permissive peptides were isolated from HLA-B^∗^15:01. By contrast, six KIR-permissive peptides were eluted from HLA-C^∗^01:02 and 38 from HLA-B^∗^46:01 ([Figure S3](#mmc1){ref-type="supplementary-material"}). These peptides comprise 7% and 21% of the total number of peptides identified for HLA-C^∗^01:02 and HLA-B^∗^46:01, respectively ([Figure 3](#fig3){ref-type="fig"} A). For both allotypes, the proportion of nonamers was greater in KIR-permissive peptides ([Figure 3](#fig3){ref-type="fig"}B). That a higher proportion of HLA-B^∗^46:01-binding peptides are KIR permissive is consistent with binding assays showing that HLA-B^∗^46:01 has a higher affinity for KIR2DL3 than HLA-C^∗^01:02 ([@bib34], [@bib35], [@bib36], [@bib50]).Figure 3KIR2DL3 Recognition of HLA-B^∗^46:01 and HLA-C^∗^01:02 Is Peptide Dependent(A) Pie charts showing the number and percentage of KIR2DL3-permissive peptides bound by HLA-C^∗^01:02 (left, blue) and HLA-B^∗^46:01 (right, orange) relative to non-permissive peptides (gray).(B) The percentage of HLA-C^∗^01:02 (blue, upper panel) and HLA-B^∗^46:01 (orange, lower panel) peptides that are KIR permissive or non-permissive (gray) divided by length.(C) Kullback-Leibler sequence logos representing the amino acid preferences for nonamer HLA-B^∗^46:01 KIR-permissive (top panel) and non-permissive (bottom panel) peptides. The colors of each amino acid correspond to their biochemical characteristics: acidic (red), basic (blue), hydrophobic (black), and polar (green). Sequence logos were generated using WebLogo ([@bib19]).(D) Heatmap matrix showing the log^10^ p values comparing the frequency of amino acids (top panel, Fisher's exact tests) and concatenated amino acid properties (bottom panel, two-sample t tests) between KIR-permissive and non-permissive peptides bound by HLA-B^∗^46:01. Increases in the frequency of an amino acid or the value of a biochemical property are shown in red, decreases in blue. Amino acids or properties that differ significantly between the groups are outlined in black.(E) Stabilization of HLA-C^∗^01:02 expression on T2 cells as determined by DT9 staining (MFI shown on x axis) in the absence of peptide (wild-type) or with selected peptides pulsed at 100 μM and measured by flow cytometry. For (E) and (F), HLA allotype specificity and KIR2DL3 reactivity are indicated in the key.(F) Degranulation of donor-derived KIR2DL3^+^ NK cells incubated with T2 cells as determined by percentage CD107a expression in the absence of peptide (wild-type) or with selected peptides pulsed at 100 μM and measured by flow cytometry (bars represent mean ± SD). Horizontal lines indicate conditions in which degranulation differs significantly from wild-type (one-way ANOVA with multiple comparisons, ^∗^p \< 0.05 and ^∗∗∗^p ≤ 0.001).

The sequences of the KIR-permissive and non-permissive nonamer peptides bound by HLA-B^∗^46:01 were compared ([Figure 3](#fig3){ref-type="fig"}C). (The low number of KIR-permissive peptides identified precluded similar analysis of HLA-C^∗^01:02.) KIR-permissive peptides have significantly increased frequency of Asn at P3 and Ser at P7 and decreased frequency of Glu at P7 and P8 ([Figure 3](#fig3){ref-type="fig"}D, upper panel). Analysis of the concatenated biochemical properties of peptides in each group showed significant differences only at the C terminus of the peptide (positions 7--9) ([Figure 3](#fig3){ref-type="fig"}D, lower panel). Here, KIR-permissive peptides are significantly more likely to have small, positively charged, and hydrophobic amino acids.

KIR2DL3-Permissive Peptides Inhibit NK Cell Cytotoxicity {#sec2.6}
--------------------------------------------------------

We next tested the capacity of KIR-permissive peptides to inhibit degranulation of NK cells. Donor-derived KIR2DL3^+^ NK cells were tested for inhibition after incubation with TAP-deficient T2 cells (which naturally express HLA-C^∗^01:02) loaded with selected peptides. Wild-type T2 cells with no exogenous peptide expressed low levels of HLA-C^∗^01:02 ([Figure 3](#fig3){ref-type="fig"}E). KIR2DL3-expressing NK cells degranulated strongly when challenged with wild-type T2 cells ([Figure 3](#fig3){ref-type="fig"}F). Pulsing T2 cells with three HLA-C^∗^01:02-specific peptides (two KIR permissive and one non-permissive) stabilized HLA-C^∗^01:02 expression to a similar extent ([Figure 3](#fig3){ref-type="fig"}E). The HLA-B^∗^46:01-specific peptide YANDFASEY stabilized HLA-C^∗^01:02 expression but to a lesser degree ([Figure 3](#fig3){ref-type="fig"}E). Both KIR-permissive peptides significantly inhibited NK cell degranulation but to different degrees ([Figure 3](#fig3){ref-type="fig"}F). Consistent with their relative affinity for KIR2DL3 ([Figure S3](#mmc1){ref-type="supplementary-material"}C), AAPLRLIAA (the higher affinity peptide) inhibited NK cell degranulation more than IAPTGHSL ([Figure 3](#fig3){ref-type="fig"}F). The non-permissive and HLA-B^∗^46:01-specific peptides did not inhibit NK cell cytotoxicity ([Figure 3](#fig3){ref-type="fig"}F).

HLA-B^∗^46:01 Has a Less Diverse Peptidome Than HLA-B^∗^15:01 {#sec2.7}
-------------------------------------------------------------

We performed two analyses to compare the diversity of each HLA peptidome. The relative sequence similarity of the amino acids in each peptidome was determined by calculating the per-position divergence in amino acid composition in five randomly selected sets of nonamer peptides. Consistent with previous studies of HLA-B and -C ([@bib52], [@bib57]) and our analysis of the raw number of distinct peptides in each peptidome ([Figure 1](#fig1){ref-type="fig"}A), we found that the HLA-B^∗^15:01 and HLA-C^∗^01:02 peptidomes had the least and most sequence similarity, respectively, with the HLA-B^∗^46:01 peptidome having intermediate sequence similarity ([Figure 4](#fig4){ref-type="fig"} A).Figure 4HLA-B^∗^46:01 Has a Restricted Peptidome(A) The information content of random subsets of N 9-mer peptides sampled from each allotype. For each value of N, this procedure was repeated 100 times and the mean is reported.(B) For each allotype, the proportion of total peptides contributed by the ten most abundant peptides. The most abundant peptide is 1. The area under each plot is proportional to the percentage, from left to right, that the ten peptides contribute: HLA-B^∗^15:01 (red), HLA-C^∗^01:02 (blue), and HLA-B^∗^46:01 (orange).(C) Graph showing the cumulative peptide abundance (%), starting at 1 with the most abundant peptide and sequentially adding peptides of decreasing abundance. Arrows show the number of peptides that constitute 50% of the total peptidome.(D) Histogram comparing the diversity of each peptidome as assessed by the Shannon-Wiener (upper panel) and Simpson (lower panel) diversity indices.

The true diversity of each peptidome was determined by comparing the abundance (intensity) of their bound peptides, as assessed by mass spectrometry. To control for the ionization potential of individual peptides, we only compared the distribution of the peptidomes. For HLA-B^∗^15:01, HLA-C^∗^01:02, and HLA-B^∗^46:01, the ten most abundant peptides contribute 18%, 34%, and 37%, respectively, to the total peptide mass ([Figure 4](#fig4){ref-type="fig"}B; [Figure S4](#mmc1){ref-type="supplementary-material"}). We next calculated the smallest number of peptides that account for 50% of the bound peptide mass. This number is 95 for HLA-B^∗^15:01, 20 for HLA-C^∗^01:02 and 20 for HLA-B^∗^46:01 ([Figure 4](#fig4){ref-type="fig"}C; [Figure S4](#mmc1){ref-type="supplementary-material"}). Thus, the HLA-B^∗^15:01 peptidome has approximately five times the diversity of the HLA-C^∗^01:02 and HLA-B^∗^46:01 peptidomes. Calculation of diversity indices for each peptidome showed that HLA-B^∗^15:01 is most diverse, followed by HLA-C^∗^01:02 and then HLA-B^∗^46:01 ([Figure 4](#fig4){ref-type="fig"}C). Together, these results show that HLA-B^∗^46:01 has a smaller peptide repertoire that is less diverse in length, abundance, and amino acid content than its more closely related parent, and they highlight the formative effect of residues 66--76.

A Predictive Model Indicates that HLA-B^∗^46:01 Differs from HLA-B^∗^15:01 in Its Capacity to Bind Pathogen-Derived Peptides {#sec2.8}
----------------------------------------------------------------------------------------------------------------------------

HLA class I peptidomes with low diversity are thought to provide protection against one or a number of closely related pathogens ([@bib16]). Epidemiologic studies suggest that the *HLA-B^∗^46:01-MICA-A5* haplotype protects against development of lepromatous leprosy, the fulminant form of disease caused by *M. leprae* ([@bib74]). Leprosy is endemic to Southeast Asia, where *HLA-B^∗^46:01* is found at high frequency ([Figures 5](#fig5){ref-type="fig"}A and 5B) ([@bib28]). We hypothesized that HLA-B^∗^46:01 might be better adapted to present peptide antigens derived from *M. leprae* than one or both of its parents. To assess this possibility, we identified 22 antigenic *M. leprae* proteins ([@bib75]), and we used a nine-amino acid-sliding window to create a library of all possible nonamer peptides. Their binding to each allotype was predicted using NetMHC 4.0 (re-trained to include data from this study) ([@bib53]).Figure 5HLA-B^∗^46:01 Differs from HLA-B^∗^15:01 in Its Capacity to Bind Pathogen-Derived Peptides(A) Inverse distance weighted map (ArcGIS) showing frequency of *HLA-B^∗^46:01* in Southeast Asia. Color scale bars correspond to allele frequency categories. Frequencies are from [allelefrequencies.net](http://allelefrequencies.net){#intref0025} ([@bib28]).(B) Map showing the disability life-adjusted life year (DALY) for leprosy per 100,000 inhabitants of Southeast Asia ([@bib44]). Disability life-adjusted life year is a measure of overall disease burden, expressed as the number of years lost due to disability, ill health, or early death.(C) Plots representing the number of nonamer peptides derived from *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Salmonella* Enteritidis, H1N1 influenza, and HIV-1 predicted to bind each allotype. The median of each plot is indicated with a solid black line. Red circles (HLA-B^∗^15:01), orange squares (HLA-B^∗^46:01), and blue triangles (HLA-C^∗^01:02) linked with black lines indicate the number of peptides derived from each antigenic protein predicted to bind the given allotype. Listed below each plot is the total number of proteins and peptides investigated. Horizontal bars with associated p values (paired t tests) indicate significant differences. Binding predictions were made using NetMHC 4.0 ([@bib53]).(D) Summary plot showing the percentage of pathogen-derived peptides bound by each allotype.(E) Principal-component analysis density plot showing the distribution of nonamer peptides bound by HLA-B^∗^46:01, divided into two clusters (HLA-C^∗^01:02-like, pink; B^∗^15:01-like, orange) on the basis of a k-nearest neighbor algorithm (top panel). The distribution of *M. leprae*-derived peptides predicted to bind HLA-B^∗^46:01 (center panel, red dots) and KIR2DL3-permissive peptides bound by HLA-B^∗^46:01 (bottom panel, red dots) is shown overlaid on the HLA-B^∗^46:01 peptidome, with the percentage of peptides falling in each cluster shown. *M. leprae*-derived peptides are significantly more likely to fall in cluster 1 (Fisher's exact test, p = 0.0028).

In support of our hypothesis, HLA-B^∗^46:01 is predicted to bind a significantly higher number of *M. leprae*-derived peptides than HLA-B^∗^15:01 ([Figure 5](#fig5){ref-type="fig"}C; [Figure S5](#mmc1){ref-type="supplementary-material"}). HLA-C^∗^01:02 also presents a higher number of *M. leprae*-derived peptides, although the difference is not significant. Similarly, both HLA-B^∗^46:01 and HLA-C^∗^01:02 are predicted to bind a significantly higher number of *Mycobacterium tuberculosis*-derived peptides than HLA-B^∗^15:01 ([Figure 5](#fig5){ref-type="fig"}C). By contrast, HLA-B^∗^46:01 binds equal or lower numbers of peptides derived from *Salmonella* Enteritidis, HIV-1, or H1N1-influenza as compared to its parents ([Figure 5](#fig5){ref-type="fig"}D). This decrease is significant for HIV-1-derived peptides ([Figure 5](#fig5){ref-type="fig"}C).

We compared the distribution of the *M. leprae*-derived peptides predicted to bind HLA-B^∗^46:01 to the distribution of the empirically determined peptides (shown in [Figure 2](#fig2){ref-type="fig"}C, center panel). To assess their relative similarity to the HLA-C^∗^01:02-like and HLA-B^∗^15:01-like peptides, we used k-nearest neighbor clustering to define two discontinuous subsets. When divided in this way, 15% of HLA-B^∗^46:01 peptides fall in HLA-C^∗^01:02-like cluster 1 and 85% of peptides fall in HLA-B^∗^15:01-like cluster 2 ([Figure 5](#fig5){ref-type="fig"}E, top panel). Comparison with *M. leprae*-derived peptides predicted to bind HLA-B^∗^46:01 shows a significantly higher percentage (25%) fall in HLA-C^∗^01:02-like cluster 1 ([Figure 5](#fig5){ref-type="fig"}E). This shift to the C^∗^01:02-like cluster 1 is also noted in KIR-permissive peptides that are more than twice as likely to fall in cluster 1 (33%) as compared to the wider HLA-B^∗^46:01 peptidome. Together these results suggest that HLA-B^∗^46:01 may provide protection against lepromatous leprosy because it is better adapted to present *M. leprae*-derived peptide antigens for immunosurveillance by NK cells and CD8^+^ T cells.

Discussion {#sec3}
==========

This study defines at high resolution the peptidomes of HLA-B^∗^46:01 and its parent allotypes. The HLA-B^∗^46:01 peptidome is restricted in the length, type, and frequency of peptides that it presents for immunosurveillance. A minority of peptides bound by HLA-B^∗^46:01 and HLA-C^∗^01:02 form ligands for the NK cell receptor KIR2DL3. HLA-B^∗^46:01 is significantly better adapted than its more closely related parent HLA-B^∗^15:01 to bind antigenic peptides derived from *M. leprae.* These distinctive functions are consistent with a model in which HLA-B^∗^46:01 rose in frequency in Southeast Asia because it provides carriers with protection from severe leprosy.

HLA-B^∗^15:01 and HLA-B^∗^46:01 share Ser77 and Asn80, the residues commonly associated with the C1 epitope. However, these residues are insufficient to confer reactivity with KIR2DL3 without HLA-C^∗^01:02-derived Val76. We show that the interaction between KIR2DL3 and HLA is dependent on the length and sequence of the bound peptide. Consistent with previous studies using exogenous peptide, we found that KIR recognition of endogenously processed peptides was most sensitive to the amino acid at position 8 and more generally to those at the C terminus of the peptide, a region that corresponds to the KIR-binding site ([@bib10]). Although no structure of KIR2DL3 in complex with its ligand has been solved, comparison with KIR2DL2 bound to HLA-C^∗^03:04 shows that Gln71 in the D1 domain forms a hydrogen bond with the amino acid at P8 ([@bib10]). The formation of this hydrogen bond brings Gln71, Ser184, and Glu187 of KIR2DL2 (residues that are identical in KIR2DL3) into such close proximity with the peptide that it constrains the size of the P8 side chain that would allow interaction with KIR. KIR2DL2 also directly contacts the amino acid at position 7 in the peptide, which is more exposed in this structure as compared to other HLA class I ([@bib23]). Interestingly, we identified one peptide, the nonamer YANDFASEY, that bound KIR2DL3 despite having Glu at P8. This finding indicates that, despite a general preference for peptides with small size and low hydrophobicity and specifically for those without Glu at P8, KIR2DL3 is able to recognize selected peptides with these characteristics. Additional functional experiments are needed to confirm this finding. Furthermore, we found that Asn at P3 is significantly more common in KIR2DL3-permissive peptides, indicating that residues outside the KIR-binding site may also influence recognition of HLA-B^∗^46:01 by KIR2DL3, presumably as a result of structural constraints imposed through the peptide backbone.

Although less stringent than the interaction between the CD8 TCR and HLA ([@bib46]), our data suggest that the majority of peptides (\>75%) presented by HLA-B^∗^46:01 and HLA-C^∗^01:02 do not provide strong ligands for KIR2DL3. Similarly, a previous study showed that KIR2DL3 recognized only a small number of exogenous peptides bound by HLA-C^∗^08:02 ([@bib65]). This specificity may explain why KIR2DL3 binding to C1 appears weaker than that of KIR2DL2 to C1 or KIR2DL1 to C2 ([@bib34], [@bib35], [@bib50]). A second implication of this specificity is that the system may be usurped by pathogens. Supporting this possibility, previous studies have shown that HIV produces escape mutants ([@bib2], [@bib37]). One example is a mutation in the p24 Gag epitope that enabled significantly better binding of KIR2DL3 to HLA-C^∗^03:04-expressing cells presenting the variant epitope ([@bib37]). Antagonism of NK cell function by peptides with weak affinity for KIR is likely to be another functional consequence of KIR2DL3 peptide selectivity. Although the specific molecular mechanisms that underlie the effect are unclear, peptides with weak affinity for inhibitory KIR antagonize those with high affinity, preventing inhibitory synapse formation and reducing the inhibitory signaling potential of NK cells ([@bib9], [@bib22]). Previous estimates indicate ∼30% of HLA-C^∗^01:02-bound peptides provide strong ligands for KIR2DL2 and 2DL3 ([@bib22]). We find that only 7% of HLA-C^∗^01:02-bound peptides and 21% of HLA-B^∗^46:01-bound peptides provide strong ligands for KIR2DL3, suggesting that peptide antagonism may play a greater functional role than previously recognized.

The HLA-B^∗^46:01 peptidome is smaller and less diverse than that of HLA-B^∗^15:01, its more closely related parent. This loss of diversity may result from reduced plasticity of the HLA-C^∗^01:02-derived α~1~ helix segment that restricts the range of permissible peptides ([@bib63], [@bib64]). A basic patch comprising R62, K66, and R69 may contribute further restriction. These residues likely contribute to the shared preference of HLA-C^∗^01:02 and HLA-B^∗^46:01 for acidic residues at position 4 and the additional length and frequency constraints that differentiate these allotypes from HLA-B^∗^15:01 ([@bib5]).

In addition to its effect on the plasticity of the peptide-binding groove, the HLA-C^∗^01:02-derived α~1~ helix segment contains the KYRV motif, which reduces cell-surface expression of HLA-C relative to HLA-A and -B ([@bib64]). Although the cell-surface expression of HLA-B^∗^46:01 has not specifically been studied, it is known to have increased intracellular retention due to prolonged association with HLA-dedicated chaperones ([@bib64]). Thus, HLA-B^∗^46:01 likely combines low-cell-surface expression with a low-diversity peptidome. By contrast, several studies have demonstrated an inverse correlation between cell-surface expression and peptidome diversity ([@bib16], [@bib68]). First described in the chicken MHC, an initial survey of four HLA-B allotypes shows a similar correlation, suggesting it is a broadly conserved feature ([@bib16]). Thus, HLA-B^∗^46:01 appears an outlier in this regard and more characteristic of HLA-C than HLA-B. The relationship between cell-surface expression and peptidome diversity within HLA-C has not been extensively studied, although HLA-C allotypes are known to exhibit differential cell-surface expression ([@bib4]).

Comparative studies have shown that MHC class I with restricted peptidomes confer protection against one or several closely related pathogens, whereas those with more diverse peptidomes confer broader disease resistance ([@bib16], [@bib68]). In the former category, HLA-B^∗^46:01 may permit prioritization of peptides from a specific pathogen, allowing an individual to mount an effective immune response. One candidate pathogen is *M. leprae* that causes leprosy, a chronic granulomatous infection of the skin and peripheral nerves. Leprosy emerged as a major infectious disease in the last 50,000 years as modern humans expanded outward across the globe from Africa ([@bib81]). Infection rates likely peaked with the mass movement of people along trade routes between Africa and Asia prior to the advent of modern medicine ([@bib40]). Leprosy is still common in many tropical regions, Southeast Asia being a notable hotbed of the disease ([@bib58]). Leprosy has exerted strong selective pressure on the human genome in general ([@bib40]) and on the *HLA* region in particular ([@bib11], [@bib25], [@bib61], [@bib62], [@bib67], [@bib79]).

Epidemiologic studies show that carriers of the *HLA-B^∗^46:01-MICA-A5* haplotype are protected against the development of lepromatous leprosy, the fulminant, life-threatening form of the disease ([@bib74]). Consistent with this finding, we show that HLA-B^∗^46:01 is predicted to bind a significantly higher number of antigenic peptides derived from *M. leprae* than its parent allotype HLA-B^∗^15:01 and a similar number to that bound by HLA-C^∗^01:02. Because *HLA-B^∗^46:01* and *HLA-C^∗^01:02* are in strong linkage disequilibrium ([@bib1]), the result is that *HLA-B^∗^46:01* carriers would have at least two *HLA class I* loci able to effectively present *M. leprae*-derived peptides. Presentation of *M. leprae* peptides to the TCR and KIR cells is likely to result in a strong cell-mediated immune response, which is a major determining factor in the clinical progression of leprosy ([@bib39], [@bib59]). Supporting a role for KIR-mediated immunity in the outcome of *M. leprae* infection, studies show that patients with the less severe tuberculoid form of leprosy have increased frequencies of activating KIR2DS2 and KIR2DS3 ([@bib24]). Together these findings support the hypothesis that *HLA-B^∗^46:01* rose in frequency because it confers protection against severe infection caused by *M. leprae.*

Arguing against this mechanism is our finding that both HLA-B^∗^46:01 and HLA-C^∗^01:02 present a higher number of peptides derived from *M. tuberculosis*. In contrast to leprosy, an epidemiologic study shows that *HLA-B^∗^46:01* carriers are more susceptible to pulmonary tuberculosis ([@bib15]). Although this study was small (only 36 subjects) and susceptibility was also linked to *HLA class II*, it suggests that the number of pathogen-derived peptides bound by a given allotype may not be the dominant mechanism that promotes disease resistance.

Intense reactivity against pathogens and a lack of collateral reactivity to self are critical features of a successful immune system. HLA-B^∗^46:01 appears able to succeed in the first requirement (although apparently with a narrow remit as epidemiologic studies show it confers susceptibility to tuberculosis, malaria, HIV, and SARS coronavirus; [@bib15], [@bib30], [@bib38], [@bib42]). However, several studies suggest that it falls short in the second, predisposing individuals to autoimmune conditions, including myasthenia gravis ([@bib14]) and Graves disease ([@bib12], [@bib31], [@bib51]), as well as to nasopharyngeal carcinoma ([@bib13]). The apparent predisposition to self-reactivity may occur because of reduced TCR diversity (a likely result of its low-diversity peptidome), increased NK cell reactivity, or an as yet undiscovered mechanism. However, these data support the notion that there is an immunological trade-off between protection against infectious disease and protection against self-reactivity. Intriguingly, this hypothesis is consistent with the clinical observation that patients with psoriasis, an autoimmune skin condition, are protected from the development of leprosy ([@bib20], [@bib32], [@bib73]).

Experimental Procedures {#sec4}
=======================

Further details are given in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Isolation of HLA Class I Complexes from 721.221 Cells {#sec4.1}
-----------------------------------------------------

Isolation and analysis of peptides were performed as previously described ([@bib48], [@bib69], [@bib76]). Briefly, 721.221 cells, which lack endogenous HLA class I expression, were transfected with constructs encoding soluble forms (sHLA) of HLA-B^∗^15:01, HLA-B^∗^46:01, and HLA-C^∗^01:02. sHLA binds a similar peptide repertoire to membrane-associated HLA class I ([@bib60]). The sHLA-peptide complexes were affinity purified from the cell supernatant on an anti-W6/32 Sepharose column, eluted, and the bound peptides dissociated from the HLA by denaturation in 10% acetic acid for 15 min at 75°C. Peptides were separated from the denatured proteins by passage through a stirred cell ultrafiltration device (3-kDa-cutoff membrane \[Millipore\]). The peptide-containing filtrate was lyophilized, re-suspended in 10% acetic acid, and separated into ∼40 fractions by reverse-phase high-performance liquid chromatography (HPLC) as described ([@bib69]). Each fraction was dried and re-suspended in 10% acetic acid for liquid chromatography-mass spectrometry (LC-MS). Approximately 25% of each HPLC fraction was injected into a nano-scale reverse-phase liquid chromatography Eksigent nano-LC-4000 (Sciex) system. Column specifications, mobile phase solvents, and the elution gradient were as described ([@bib69]). Eluted fractions were ionized using a NanoSpray III (Sciex) ion source into a Sciex TripleTOF 5600 mass spectrometer.

Isolation and Analysis of KIR-Permissive Peptide Ligands from 721.221 Cells {#sec4.2}
---------------------------------------------------------------------------

Biotinylated KIR2DL3 monomer was incubated with streptavidin-coated microbeads (Thermo Fisher Scientific), according to the manufacturer's instructions, and washed to remove excess KIR2DL3. Then 300 μl containing 75 μg W6/32-purified sHLA-B^∗^15:01, sHLA-C^∗^01:02, and sHLA-B^∗^46:01 material was divided into three equal aliquots each and incubated for 16 hr at 4°C with KIR2DL3-conjugated microbeads, unconjugated blank beads, or no beads. KIR2DL3-conjugated beads were added in 3.5 molar excess of KIR2DL3 to sHLA. Following incubation, each 25-μg aliquot was washed with 30 bead volumes, and ligand identification was performed in data-independent mode (DIA) in triplicate.

NK Cell Cytotoxicity Assay Using T2 Cell Lines {#sec4.3}
----------------------------------------------

To test the effect of specific peptides, T2 cells were incubated in serum-free RPMI media overnight at 26°C in the presence of 100 μM synthetic peptide (GenScript). Cells were washed and stained with the HLA-C-specific DT9 antibody (EMD Millipore). Peptide stabilization was assessed by flow cytometry on an Accuri C6 benchtop flow cytometer (BD Biosciences).

NK cells were isolated from five healthy *KIR A haplotype* and *HLA-C1* homozygous donors, and they were stimulated overnight with 500 units/mL recombinant human IL-2 (R&D Systems) in RPMI 10% complete media. T2 cells (3 × 10^4^) were incubated with 100 μM peptide (Genscript) overnight in serum-free media at 26°C, washed, and re-suspended in serum-free media with anti-CD107a-TexasRed antibody (eBioscience). T2 cells were incubated with NK cells at a target:effector ratio of 10:1 for 3.5 hr in serum-free media with 500 units/mL recombinant human IL-2. Surface staining was performed using anti-KIR2DL2/3-APC GL183 (Beckman Coulter) and anti-KIR3DL1-FITC DX9 (BioLegend) to identify KIR2DL3^+^/KIR3DL1^−^ NK cells. Following surface staining, cells were treated with live/dead orange (Life Sciences) and fixed (Cytofix, BD Biosciences). Cells were analyzed on an LSR II cytometer (BD Biosciences) at the Stanford Flow Cytometry Core Facility. A representative gating strategy is shown in [Figure S5](#mmc1){ref-type="supplementary-material"}B.

Statistical and Bioinformatic Methods {#sec4.4}
-------------------------------------

### Calculation of Peptidome Sequence Similarity {#sec4.4.1}

The information content for each peptidome was calculated as the summed Kullback-Leibler distance (KLD) over the positions in the binding motif. A random subset of N 9-mer peptides was sampled from each allotype, and amino acids frequencies (p~aa~) were estimated using sequence weighting and pseudo counts correction for a low number of observations, as previously described ([@bib54]). The KLD at each position was calculated as sum 2^∗^ p~aa~ ^∗^ log2(p~aa~/q~aa~), where q~aa~ is the background frequency of amino acid (aa). For each value of N, this procedure was repeated 100 times and the mean is reported.

### Covariation Analysis {#sec4.4.2}

To search for covariation between peptide positions, coupling terms were calculated as described ([@bib43]) and plotted as a heatmaps, processed and analyzed with custom Perl and MATLAB (MathWorks) scripts as described ([@bib49]). Scripts are available upon request.

### PCA {#sec4.4.3}

For each amino acid in a peptide, four biochemical properties (molecular weight, hydropathy index, surface area, and isoelectric point) were determined. Thus, 36 variables were generated for each nonamer peptide. A custom R script (available at [www.stanford.edu/group/parhamlab/software](http://www.stanford.edu/group/parhamlab/software){#intref0010}) was used to generate PCA plots for nonamer peptides from the three HLA class I allotypes. The k-nearest neighbor algorithm (k = 15) ([@bib72]) was used to cluster the HLA-B^∗^46:01 peptidome by similarity to those of HLA-B^∗^15:01 and HLA-C^∗^01:02. Comparison of the distribution of empirically determined HLA-B^∗^46:01 peptides to either *M. leprae*-derived peptides predicted to bind HLA-B^∗^46:01 or HLA-B^∗^46:01 KIR-permissive peptides was made using a Fisher's exact test.

### Analysis of KIR-Permissive versus Non-permissive Peptides {#sec4.4.4}

Fisher's exact (specific amino acids) and two sample t tests (concatenated properties) were used to determine the magnitude of frequency changes at each position of the peptide between KIR-permissive and non-permissive groups.

### NK Cell Degranulation Assay {#sec4.4.5}

One-way ANOVA tests with multiple comparisons were used to quantify the magnitude of changes in NK cell degranulation (percentage CD107a expression) between KIR-permissive and non-permissive peptides bound by HLA-C^∗^01:02.

### Prediction of Pathogen-Derived Peptide Binding to HLA-B^∗^15:01, HLA-B^∗^46:01, and HLA-C^∗^01:02 {#sec4.4.6}

A literature search identified a set of antigenic proteins derived from five pathogens: *M. leprae* (taken from Table 2 in [@bib75]), *M. tuberculosis* (taken from Table 1 in [@bib45]), *S.* Enteritidis (taken from Table 3 in [@bib17]), and the complete proteome of HIV-1 ([@bib21]) and H1N1 influenza A, strain PR1934 (NIAID Influenza Genome Sequencing Consortium, [www.fludb.org](http://www.fludb.org){#intref0015}). A nine-amino acid-sliding window was used to create a library of all possible nonamer peptides from each protein, and their binding to each allotype was predicted with NetMHC 4.0 ([@bib53]). The model used to make these predictions was trained on 436 nonamer peptides and 2,180 random natural negative nonamer peptides using the NNAlign method ([@bib3]). Percentile rank scores were estimated from the distribution of prediction scores of 100,000 random natural 9-mer peptides. Peptides were considered to bind if their predicted percentile score was ≤2%. Paired t tests were used to compare the number of peptides bound by HLA pairs.

All statistical calculations were performed in GraphPad Prism 6.0 with α = 0.05.
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